NeuroSense Therapeutics Announces Registered Direct Offering
Ticker: NRSNW · Form: 6-K · Filed: Apr 12, 2024 · CIK: 1875091
| Field | Detail |
|---|---|
| Company | Neurosense Therapeutics LTD. (NRSNW) |
| Form Type | 6-K |
| Filed Date | Apr 12, 2024 |
| Risk Level | medium |
| Pages | 6 |
| Reading Time | 7 min |
| Key Dollar Amounts | $1.50, $1.4999, $4.47 million, $0.0001, $50,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: offering, capital-raise, securities
TL;DR
NeuroSense selling shares directly to an institution on April 10th. Details TBD.
AI Summary
On April 10, 2024, NeuroSense Therapeutics Ltd. entered into a Securities Purchase Agreement to issue and sell shares in a registered direct offering to an institutional purchaser. The filing does not specify the number of shares or the total dollar amount of the offering.
Why It Matters
This registered direct offering indicates NeuroSense Therapeutics is raising capital, which could fund ongoing research and development or operational expenses.
Risk Assessment
Risk Level: medium — Registered direct offerings can dilute existing shareholders and the lack of specific financial details in this initial report introduces uncertainty.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Filer of the 6-K report and party to the agreement
- April 10, 2024 (date) — Date of the Securities Purchase Agreement
- Securities Purchase Agreement (document) — Agreement for the registered direct offering
- institutional purchaser (company) — The buyer in the registered direct offering
FAQ
What is the total dollar amount of the registered direct offering?
The filing does not specify the total dollar amount of the registered direct offering.
How many shares is NeuroSense Therapeutics Ltd. issuing in this offering?
The filing does not specify the number of shares being issued.
Who is the institutional purchaser involved in the Securities Purchase Agreement?
The filing refers to the purchaser as 'the institutional purchaser identified on the signature page thereto' but does not name them specifically.
What is the purpose of this registered direct offering?
The filing states the company agreed to issue and sell shares but does not explicitly state the purpose of the offering.
When was the Securities Purchase Agreement entered into?
The Securities Purchase Agreement was entered into on April 10, 2024.
Filing Stats: 1,770 words · 7 min read · ~6 pages · Grade level 12.8 · Accepted 2024-04-12 16:30:07
Key Financial Figures
- $1.50 — Shares”), at an offering price of $1.50 per share; and (ii) an aggregate of 1,2
- $1.4999 — rrants”), at an offering price of $1.4999 per Pre-Funded Warrant, for gross proce
- $4.47 million — nt, for gross proceeds of approximately $4.47 million before deducting the placement agent fe
- $0.0001 — Ordinary Share at an exercise price of $0.0001 per share. The Pre-Funded Warrants are
- $50,000 — he placement agent fee in the form of a $50,000 fee in cash and to receive 70,964 of ou
- $25,000 — the offering in an amount not to exceed $25,000. 1 The foregoing summaries of the Pla
- $4.5 Million — “NeuroSense Announces Pricing of $4.5 Million Registered Direct Offering and Concurre
Filing Documents
- ea0203662-6k_neurosense.htm (6-K) — 26KB
- ea020366201ex4-1_neurosense.htm (EX-4.1) — 82KB
- ea020366201ex5-1_neurosense.htm (EX-5.1) — 8KB
- ea020366201ex5-2_neurosense.htm (EX-5.2) — 14KB
- ea020366201ex10-1_neurosense.htm (EX-10.1) — 46KB
- ea020366201ex10-2_neurosense.htm (EX-10.2) — 228KB
- ea020366201ex10-3_neurosense.htm (EX-10.3) — 91KB
- ea020366201ex99-1_neurosense.htm (EX-99.1) — 11KB
- ex5-1_001.jpg (GRAPHIC) — 12KB
- ex5-1_002.jpg (GRAPHIC) — 40KB
- ex5-2_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-032576.txt ( ) — 582KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: April 12, 2024 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Officer 4